| Identification | Back Directory | [Name]
Dapaconazole | [CAS]
1269726-67-1 | [Synonyms]
Dapaconazole
1-[2-(2,4-Dichlorophenyl)-2-[[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1H-imidazole
1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[[4-(trifluoromethyl)phenyl]methoxy]ethyl]- | [Molecular Formula]
C19H15Cl2F3N2O | [MDL Number]
MFCD28963959 | [MOL File]
1269726-67-1.mol | [Molecular Weight]
415.24 |
| Chemical Properties | Back Directory | [Boiling point ]
512.8±50.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [solubility ]
DMSO:100.0(Max Conc. mg/mL);240.82(Max Conc. mM) | [form ]
Solid | [pka]
6.66±0.12(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
Dapaconazole, as an antifungal agent, inhibits sterol 14α-demethylase cytochrome P450 activity with an IC50 of 1.4 μM[1]. | [in vivo]
Dapaconazole (20 mg/kg; p.o.) shows that the bioavailability is 97.3 %[1]. | Animal Model: | Male beagle dogs[1] | | Dosage: | 20 mg/kg (Pharmacokinetic Analysis) | | Administration: | P.o. | | Result: | Showed that the bioavailability was 97.3 %.
|
| [IC 50]
CYP26: 1.4 μM (IC50) | [References]
[1] Juliana SP, et al. Pharmacokinetics of Dapaconazole, A Novel Antifungal Agent, in Beagle Dogs and Inhibition of Cytochrome P450 Family 51. J Eur Acad Dermatol Venereol. 2018 Jun 10. |
|
|